Relay’s zovegalisib hits in phase II vascular anomalies trial

Relay Therapeutics’ zovegalisib (RLY-2608) posted a 60% volumetric response in a phase II trial for PIK3CA-driven vascular anomalies, signaling meaningful clinical efficacy. The PI3Ka inhibitor is also being advanced in late-stage trials for HR+/HER2- PIK3CA-mutated advanced breast cancer, and analyst Andrew Berens sees vascular anomalies as a second indication supporting up to $2.8B in peak revenue.

Analysis

This is less about a single readout and more about de-risking the platform thesis. A clean signal in a second, mechanistically distinct indication expands the addressable market and reduces the odds that RLAY is just a one-shot oncology story; that matters because multi-indication optionality is what supports premium-duration biotech multiples. The more subtle implication is that the asset’s value is now increasingly driven by breadth of efficacy across PI3K-driven biology, which can support a re-rating even before any one late-stage readout lands.

The biggest second-order winner is not just RLAY equity; it is the deal narrative around selective PI3K agents. If the efficacy holds, large-cap oncology franchises will likely re-screen competitive assets and combination stacks, which could pressure legacy PI3K approaches and benefit platform-centric developers with cleaner tolerability. Conversely, a stronger profile here raises the bar for competitors in the class and could make adjacent assets look structurally inferior on differentiation, not just efficacy.

The main risk is a classic biotech mismatch between early enthusiasm and late-stage monetization. The market can price in a multi-billion opportunity quickly, but the path to that outcome still hinges on durability, dosing, and whether the signal generalizes across heterogeneous patient subtypes; any safety or durability miss over the next 6-18 months would compress the story hard. The contrarian view is that consensus may be underestimating how much of the upside is already tied to ambitious peak-sales assumptions, so the right trade is not to chase outright, but to own optionality while capping downside.

Near term, the stock should react more to pipeline credibility than to fundamental cash flow, which means volatility will likely stay high into the next clinical updates. In that regime, the upside is most leveraged if management can convert this into additional partnering leverage or improved probability-of-success assumptions across the franchise. If subsequent data broadens the efficacy signal, the name can rerate on both higher peak sales and lower perceived development risk; if not, the market may quickly compress the multiple back to a single-asset biotech discount.

Key Decisions for Investors

• Go long RLAY on weakness over the next 1-2 sessions, sized as a catalyst trade rather than a core position; target a 15-25% upside move if the market starts pricing higher platform probability, with a 10-12% stop if follow-through fails.
• Buy RLAY calls 2-4 months out to capture the next data/partnering catalyst window; prefer spreads to reduce theta burn, with payoff skewed to a continuation of the re-rating rather than a single-day pop.
• If you already own RLAY, trim into strength and re-enter on pullbacks: the market is likely to extrapolate peak-sales headlines faster than it will validate them, so upside can be harvested into the first move.
• Pair trade: long RLAY / short a less-differentiated PI3K-adjacent oncology name or broader biotech basket over 1-3 months; the relative trade benefits if selective efficacy becomes the key differentiation variable.
• Watch for partnership/licensing headlines over the next 3-6 months; if a larger pharma signs on, add aggressively, because that would convert scientific optionality into external validation and materially compress financing risk.